Hybrid mRNA Nano Vaccine Potentiates Antigenic Peptide Presentation and Dendritic Cell Maturation for Effective Cancer Vaccine Therapy and Enhances Response to Immune Checkpoint Blockade (Adv. Healthcare Mater. 32/2023)

Nano Vaccines In article 2301261 by Hongchen Gu and co-workers, a hybrid mRNA-based nano vaccine is reported with the potential to promote the peptide presentation of intratumoral dendritic cells and macrophages. With the anti-PD-1 antibody, the nano vaccine arouses robust tumor suppression in murine models with large tumor burdens (initial volume > 300 mm3). The mRNA vaccine represents a transformable platform and augments response to ICB.